Hematological and biochemical abnormalities parameters in the severity of COVID-19
- Conditions
- Coronavirus as the cause of diseases classified elsewhere, (2) ICD-10 Condition: B998||Other infectious disease,
- Registration Number
- CTRI/2020/10/028523
- Lead Sponsor
- Parumkhswami Medicall College and Shree Krishna Hospital
- Brief Summary
Coronavirus disease (COVID-19) is an infectious disease caused by a new virus. The disease causes respiratory illness (like the flu) with signs and symptoms such as a cough, fever, and in more severe cases, difficulty breathing.
To address this outbreak, it is requiring to provide a solution including diagnostics, medical devices, Sanitizers, Disinfectants, masks, ventilators, goggles, and other medical equipment.
The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from the initial diagnosis to patient monitoring and treatment.
In addition to the relationship between results of hematological and biochemical tests and the severity of Covid 19 disease that will be helpful for physicians to determine the appropriate treatment.
As tocilizumab is a humanized monoclonal antibody against interleukin-6. In addition to the early indications and clinical benefit of tocilizumab in severe COVID-19 disease, clinical studies are needed to clarify the elevation of IL-6 in the severe COVID-19.
The current study was designed to study the abnormalities of the hematological and biochemical tests in COVID-19 patients.
**1.1** **Objectives of the present study**
Ø To investigate the ability of C-reactive protein (CRP), ferritin, interleukin-6 (IL-6), and procalcitonin (PCT) to predict mild and severe cases of COVID-19.
Ø To evaluate the accuracy of others laboratory parameters (CBC, Differential Count, Thrombin Time, D DIMER and Lactate Dehydrogenase) in predicting cases with positive RT-PCR for COVID-19.
Ø To assess the role of tocilizumab in reducing risk in patients with severe pneumonia COVID-19 and its association with interleukin-6.
**2-** **Material and method:**
The Shree Krishna Hospital was designated to treat COVID-19 patients in Anand – Gujarat.
The study will be carried out at biochemistry department of the central diagnostic laboratory of the Shree Krishna Hospital attached to Pramukhswami Medical College, Karamsad.
We will include all cases of COVID-19 were admitted in this hospital between August, 2020, and September, 2020.
**- Study design:** Retrospective study
- **Inclusion & exclusion criteria, sampling procedures etc.**
**Inclusion:** - Patients with positive RT-PCR for COVID-19.
**Exclusion:** - Patients with positive serology without conformed by RT-PCR for COVID-19.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 200
Patients with positive RT-PCR for COVID-19.
Patients with positive serology without conformed by RT-PCR for COVID-19.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the ability of C-reactive protein (CRP), ferritin, interleukin-6 (IL-6), and procalcitonin (PCT) to predict mild and severe cases of COVID-19. Three month
- Secondary Outcome Measures
Name Time Method To evaluate the accuracy of others laboratory parameters (CBC, Differential Count, Thrombin Time, D DIMER and Lactate Dehydrogenase) in predicting cases with positive RT-PCR for COVID-19. Three Month
Trial Locations
- Locations (1)
PSMC, Karmsad
🇮🇳Anand, GUJARAT, India
PSMC, Karmsad🇮🇳Anand, GUJARAT, IndiaDr Hitesh ShahPrincipal investigator9825357205hiteshns@charutarhealth.org